VSTM Latest Headlines

Verastem updates oncology strategy in new corporate presentation

at www.tipranks.com (Thu, 8-Jan 4:51 PM)

Immuneering plummets following phase 2 data of atebimetinib for pancreatic cancer

at seekingalpha.com (Wed, 7-Jan 4:59 PM)

Verastem Oncology Shifts Focus After RAMP 203 Trial: Strategic Pivot Highlights Promise of Next-Gen KRAS G12D Inhibitor

Market Chameleon (Tue, 30-Dec 8:59 AM)

Verastem Oncology Prices $90 Million Offering to Accelerate Cancer Therapy Pipeline

Market Chameleon (Fri, 14-Nov 8:18 AM)

Verastem Oncology's Q3 Performance Underscores Momentum in RAS/MAPK Drug Development

Market Chameleon (Tue, 4-Nov 9:16 AM)

Verastem's VS-7375 Shows 41% Response Rate and 96.7% Disease Control in Heavily Treated Pancreatic Cancer Patients

Market Chameleon (Mon, 20-Oct 7:55 AM)